NDA 020896 · Cheplapharm
Xeloda
Capecitabine · Oral · Nucleoside Metabolic Inhibitor
NovelAccelerated approvalPriority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: Oct 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Apr 30, 1998
Approved uses
14
Original approval plus efficacy supplements
Registered trials
2,517
624 Phase 3, 436 recruiting
FAERS reports
91,426
75,506 serious, 18,299 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. Avoid use of XELODA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency [see Warnings and Precautions (5.1) ]. Increased risk of bleeding with concomitant use of Vitamin K antagonists • Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with oral vitamin K antagonists, such as warfarin [see Warnings and Precautions (5.2) , Drug Interactions (7.2) ] . • Clinically significant increases in...
What it is approved for
From the label in effect Feb 5, 2026.
XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer XELODA is indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal...
Mechanism: Capecitabine is metabolized to fluorouracil in vivo. Both normal and tumor cells metabolize fluorouracil to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N 5-10 -methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA,...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2022 Supplement 49 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 47 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 45 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 51 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 48 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 46 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 44 · Efficacy LabelLetterReview
- Dec 14, 2022 Supplement 50 · Efficacy LabelLetterReview
- Dec 10, 2013 Supplement 32 · Efficacy · priority review LetterLabelPediatric Written Request
- Feb 5, 2011 Supplement 26 · Efficacy LetterLabel
- Jun 15, 2005 Supplement 16 · Efficacy LetterLabel
- Sep 7, 2001 Supplement 10 · Efficacy · priority review LabelReviewLetter
- Apr 30, 2001 Supplement 6 · Efficacy ReviewLetter
- Apr 30, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelLetterReview
2 products under this application
- XELODA · CAPECITABINE 150MG · TABLET, ORAL · Discontinued · TE AB
- XELODA · CAPECITABINE 500MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Capecitabine" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and IIIPivotal-lookingStatus unknown
State Key Laboratory of Cancer BiologyResearch network
NCT01196260 · 8,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2020
Drug: Capecitabine and Oxaliplatin · For: Colorectal Cancer
Sites: Xi'an, China
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal CancerPivotal-lookingCompleted
Cancer Research UK, GlasgowAcademic, hospital or other
NCT00749450 · 6,088 participants · Start Mar 2008 · Primary completion Nov 2017
Drug: capecitabine; fluorouracil and 1 more · For: Colorectal Cancer
Sites: Glasgow, United Kingdom
- Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II EvaluationPivotal-lookingStatus unknown
Technische Universität DresdenAcademic, hospital or other
NCT04089631 · 4,812 participants (planned) · Start Jun 26, 2020 · Primary completion Jun 2023
Drug: Capecitabine · For: Colon Cancer Stage II
Sites: Dresden, Germany
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerPivotal-lookingCompleted
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteAcademic, hospital or other
NCT00646607 · 3,756 participants · Start Jun 2007 · Primary completion Apr 2013
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin); FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin) · For: Colon Cancer
Sites: Casale Monferrato, Italy; Ancona, Italy; Fabriano, Italy · 111 sites in all
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00112918 · 3,451 participants · Start Dec 2004 · Primary completion Jun 2010
Drug: Bevacizumab; Capecitabine and 3 more · For: Colorectal Cancer
Sites: Los Angeles, California
- A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)Pivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00196872 · 3,000 participants (planned) · Start Jul 2004 · Primary completion Jun 2014
Drug: Epirubicine; Cyclophosphamide and 3 more · For: Breast Cancer
Sites: Frankfurt, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea13,713
- death8,788
- nausea8,520
- palmar-plantar erythrodysaesthesia syndrome6,691
- fatigue6,544
- vomiting6,327
- disease progression6,093
- malignant neoplasm progression4,032
- off label use3,895
- asthenia3,441
- decreased appetite3,305
- neutropenia3,161
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 642 |
| 2005 | 823 |
| 2006 | 959 |
| 2007 | 1,734 |
| 2008 | 2,153 |
| 2009 | 2,779 |
| 2010 | 2,889 |
| 2011 | 2,581 |
| 2012 | 5,959 |
| 2013 | 4,267 |
| 2014 | 3,115 |
| 2015 | 2,958 |
| 2016 | 2,929 |
| 2017 | 6,962 |
| 2018 | 4,771 |
| 2019 | 5,424 |
| 2020 | 6,546 |
| 2021 | 7,740 |
| 2022 | 7,175 |
| 2023 | 5,940 |
| 2024 | 5,255 |
| 2025 | 4,705 |
| 2026 | 3,120 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- SPOTlight on GLOW.
Derks S, van Laarhoven HWM · Cell Rep Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Primrose JN, Fox RP, Palmer DH, et al. · Lancet Oncol 2019 · Clinical Trial, Phase III, Comparative Study
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Multicenter Study
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Multicenter Study
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.